Xilio Therapeutics Inc. Common Stock XLO · Stock Open Xilio Therapeutics Inc. Common Stock in new tab
Xilio Therapeutics Inc. Common Stock Analysis (XLO)
Is Xilio Therapeutics Inc. Common Stock a good investment? Xilio Therapeutics Inc. Common Stock (XLO) is currently trading at 9.02 USD.
Earnings Schedule: Xilio Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.58.
Investor FAQ
Does Xilio Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Xilio Therapeutics Inc. Common Stock?
Xilio Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.32.
Company Profile
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| March 16, 2026 | 1:14 |
Community Discussion